Bavarian Nordic Receives Health Canada Approval of IMVAMUNE Smallpox Vaccine
(Thomson Reuters ONE) -
KVISTGAARD, Denmark, November 22, 2013 - Bavarian Nordic A/S (OMX: BAVA, OTC:
BVNRY) announced today that Health Canada has granted a Notice of Compliance
approving IMVAMUNE® for active immunization against smallpox in a public health
emergency. IMVAMUNE is indicated for persons 18 years of age and older who are
contraindicated to replicating smallpox vaccines. This includes individuals with
immune deficiencies and skin disorders.
Health Canada is the second regulatory body to approve the company's smallpox
vaccine which earlier this year was approved by the European Commission for use
in the general adult population in all 28 EU countries and Iceland,
Liechtenstein and Norway, where it is marketed under the trade name IMVANEX®.
Since 2008, Bavarian Nordic has collaborated with the Canadian Government to
address their biological preparedness requirements. The company was initially
awarded a contract to supply 20,000 doses of IMVAMUNE to the Canadian armed
forces, followed by a replacement order in 2012. The original contract also
provided funding for filing a New Drug Substance application for IMVAMUNE.
"The approval of IMVAMUNE in Canada continues our track record of successfully
working with governments to address their biological preparedness requirements.
We have partnered with the U.S. government for more than a decade on the
development of our smallpox vaccine and we are delighted that Canada now
leverages on this successful partnership," said Anders Hedegaard, President and
CEO of Bavarian Nordic. "This approval provides further validation of our MVA-BN
vaccine technology platform which we have successfully developed and
commercialized."
Asger Aamund
Chairman of the Board
Contacts
Anders Hedegaard, President & CEO. Phone +45 23 20 30 64
About IMVAMUNE (MVA-BN)
IMVAMUNE is based on the MVA-BN vaccine platform technology (Modified Vaccinia
Ankara - Bavarian Nordic). MVA-BN is a robust and adaptable vaccine platform
suitable for addressing a wide variety of infectious diseases, including
biological threats. In addition to developing MVA-BN as a safer smallpox vaccine
essential to protecting the immune-compromised population, Bavarian Nordic has
conducted preclinical and clinical studies of recombinant MVA-BN-based vaccines
for a variety of infectious diseases and numerous types of cancer. More than
7,300 individuals, nearly 1,000 of whom are immunocompromised, have been
vaccinated with MVA-BN-based vaccines, showing the platform displays high
immunogenicity and a favorable safety profile.
An advantage of MVA-BN is the virus' inability to replicate in a vaccinated
individual. The replication cycle is blocked at a very late stage, which ensures
that new viruses are not generated and released. This means that the virus
cannot spread in the vaccinated person and none of the serious side effects
normally associated with replicating vaccinia viruses have been seen with MVA-
BN.
Bavarian Nordic recently completed the delivery of the first 20 million doses of
IMVAMUNE to the U.S. Strategic National Stockpile. The U.S. government has also
exercised a contract option to purchase an additional 8 million doses in 2013
and 2014. Several other governments around the world have procured the vaccine
for their preparedness stockpiles.
About Bavarian Nordic
Bavarian Nordic is an international biotechnology company developing and
manufacturing novel cancer immunotherapies and vaccines for infectious diseases.
Lead product candidates are PROSTVAC®, an immunotherapy product candidate for
advanced prostate cancer that is the subject of an ongoing pivotal Phase 3
clinical trial and IMVAMUNE®, a non-replicating smallpox vaccine candidate in
Phase 3 development, which is being developed and supplied for emergency use to
the U.S. Strategic National Stockpile under a contract with the U.S. Government.
The vaccine is approved in Canada under the trade name IMVAMUNE and in the
European Union under the trade name IMVANEX®.
Bavarian Nordic's shares are listed on NASDAQ OMX Copenhagen under the symbol
BAVA (Reuters: BAVA.CO, Bloomberg: BAVA.DC). The company has a sponsored Level
1 ADR program listed in the US (OTC) under the symbol BVNRY.
For more information, visit www.bavarian-nordic.com.
Forward-looking statements
This announcement includes forward-looking statements that involve risks,
uncertainties and other factors, many of which are outside of our control that
could cause actual results to differ materially from the results discussed in
the forward-looking statements. Forward-looking statements include statements
concerning our plans, objectives, goals, future events, performance and/or other
information that is not historical information. We undertake no obligation to
publicly update or revise forward-looking statements to reflect subsequent
events or circumstances after the date made, except as required by law.
201322uk:
http://hugin.info/100065/R/1744903/587290.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Bavarian Nordic A/S via Thomson Reuters ONE
[HUG#1744903]
Unternehmensinformation / Kurzprofil:
Datum: 22.11.2013 - 07:30 Uhr
Sprache: Deutsch
News-ID 319436
Anzahl Zeichen: 6057
contact information:
Town:
Kvistgård
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 158 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Bavarian Nordic Receives Health Canada Approval of IMVAMUNE Smallpox Vaccine"
steht unter der journalistisch-redaktionellen Verantwortung von
Bavarian Nordic A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
